Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A Validated Echocardiographic Risk Model for Predicting Outcome Following ST-segment Elevation Myocardial Infarction

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Assessment of Predictors of Left Atrial Volume Response to a Transcatheter InterAtrial Shunt Device (from the REDUCE LAP-HF Trial)

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Fabrizio D'Ascenzo
  • Salma Taha
  • Claudio Moretti
  • Pierluigi Omedè
  • Walter Grossomarra
  • Jonas Persson
  • Morten Lamberts
  • Willem Dewilde
  • Andrea Rubboli
  • Sergio Fernández
  • Enrico Cerrato
  • Ilaria Meynet
  • Flavia Ballocca
  • Umberto Barbero
  • Giorgio Quadri
  • Francesca Giordana
  • Federico Conrotto
  • Davide Capodanno
  • James DiNicolantonio
  • Sripal Bangalore
  • Matthew Reed
  • Pascal Meier
  • Giuseppe Zoccai
  • Fiorenzo Gaita
View graph of relations

The optimal antiaggregant therapy after coronary stenting in patients receiving oral anticoagulants (OACs) is currently debated. MEDLINE and Cochrane Library were searched for studies reporting outcomes of patients who underwent PCI and who were on triple therapy (TT) or dual-antiplatelet therapy (DAPT) with aspirin and clopidogrel or dual therapy (DT) with OAC and clopidogrel. Major bleeding was the primary end point, whereas all-cause death, myocardial infarction (MI), stent thrombosis, and stroke were secondary ones. Results were reported for all studies and separately for those deriving from randomized controlled trials or multivariate analysis. In 9 studies, 1,317 patients were treated with DAPT and 1,547 with TT. DAPT offered a significant reduction of major bleeding at 1 year for overall studies and for the subset of observational works providing adjusted data (odds ratio [OR] 0.51, 95% confidence interval [CI] 0.39 to 0.68, I2 60% and OR 0.36, 95% CI 0.28 to 0.46) compared to TT. No increased risk of major adverse cardiac events (MACE: death, MI, stroke, and stent thrombosis) was reported (OR 0.71, 95% CI 0.46 to 1.08), although not deriving from randomized controlled trials or multivariate analysis. Six studies tested OAC and clopidogrel (1,263 patients) versus OAC, aspirin, and clopidogrel (3,055 patients) with a significant reduction of bleeding (OR 0.79, 95% CI 0.64 to 0.98), without affecting rates of death, MI, stroke, and stent thrombosis (OR 0.90, 95% CI 0.69 to 1.23) also when including clinical data from randomized controlled trials or multivariate analysis. In conclusion, compared to TT, both aspirin and clopidogrel and clopidogrel and OAC reduce bleeding. No difference in major adverse cardiac events is present for clopidogrel and OAC, whereas only low-grade evidence is present for aspirin and clopidogrel.

Original languageEnglish
JournalThe American journal of cardiology
Issue number9
Pages (from-to)1185-93
Number of pages9
Publication statusPublished - 1 May 2015

    Research areas

  • Administration, Oral, Anticoagulants, Aspirin, Drug Therapy, Combination, Hemorrhage, Humans, Myocardial Ischemia, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Randomized Controlled Trials as Topic, Stents, Ticlopidine, Treatment Outcome

ID: 45925186